Application of TDGF-1 (teratocarcinoma-derived growth factor-1) truncated micro-molecule polypeptide in anti-hepatic fibrosis
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- JILIN UNIV FIRST HOSPITAL
- Publication Date
- 2019-12-20
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention belongs to the field of biomedicine and relates to the application of TDGF-1 truncated small molecular polypeptide in anti-hepatic fibrosis. Background technique
[0002] Liver fibrosis is a pathological change common to almost all chronic liver diseases progressing to the end stage, and its essence is the fibrous tissue scar after liver inflammation and necrosis. Chronic liver diseases that lead to liver fibrosis include alcoholic liver disease, nonalcoholic steatohepatitis (NASH), and chronic hepatitis caused by viral infection. If the disease continues to progress, liver fibrosis will develop into cirrhosis and liver cancer. Therefore, timely and active intervention in patients with liver fibrosis is very important to reduce the incidence of end-stage liver disease.
[0003] The essence of liver fibrosis is a scar reaction, which can be caused by various liver injuries, including poisoning, metabolism and virus attack. Underlying th...